Sa1899 CLINICAL IMPLICATIONS OF INFLIXIMAB AND ADALIMUMAB THERAPEUTIC DRUG MONITORING BEFORE AND AFTER THE IMPLEMENTATION OF CORRECTIVE MEASURES FOR THE HOMOGENEOUS MOBILITY SHIFT ASSAY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

2020 ◽  
Vol 158 (6) ◽  
pp. S-471
Author(s):  
Konstantinos Papamichail ◽  
William Clarke ◽  
Katharine A. Germansky ◽  
Sarah N. Flier ◽  
Joseph D. Feuerstein ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Therapeutic Drug Monitoring ◽  
Bowel Disease ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Clinical Implications ◽  
Mobility Shift ◽  
Before And After ◽  
Inflammatory Bowel ◽  
Mobility Shift Assay

Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease

2020 ◽  
Vol 65 (4) ◽  
Author(s):  
Daniela Pugliese ◽  
Giuseppe Privitera ◽  
Fabrizio Pizzolante ◽  
Antonio Gasbarrini ◽  
Luisa Guidi ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Therapeutic Drug Monitoring ◽  
Bowel Disease ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Inflammatory Bowel

scholarly journals P546 Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease

2019 ◽  
Vol 13 (Supplement_1) ◽  
pp. S387-S387
Author(s):  
N Torres ◽  
D Martín Arranz ◽  
M Sánchez Azofra ◽  
E Martín Arranz ◽  
L Garcia ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Therapeutic Drug Monitoring ◽  
Bowel Disease ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document